{"page_content": "ESG R eport 2022\nDiscussion, by world region, of management process for  \nensuring quality and patient safety during clinical trials  \nSASB: HC-BP-210A.1\nAgios follows all review and approval procedures required by \napplicable laws and regulations before initiating clinical research. \nAgios protects patient safety and well-being through appropriate \ninformed consent procedures and Good Clinical Practices. For more \ninformation, see Agios\u2019 Code of Business Conduct and Ethics .\nNumber of FDA Sponsor Inspections related to clinical  \ntrial management and pharmacovigilance that resulted  \nin: (1) Voluntary Action Indicated (VAI) and (2) Official  \nAction Indicated (OAI)  \nSASB: HC-BP-210A.2\n2 FDA sponsor inspections and zero findings (VAI or OAI).\nTotal amount of monetary losses as a result of legal proceedings \nassociated with clinical trials in developing countries  \nSASB: HC-BP-210A.3\nNo monetary losses resulting from legal proceedings in 2021.  \nFor more information, see Agios\u2019 2021 10-K .Safety of Clinical Trial Participants\nCommitted to the Humane  \nTreatment of Animals in Research\nIn early 2022, Agios achieved American Association for Accreditation of \nLaboratory Animal Care (AAALAC) accreditation for our animal research \nfacility. AAALAC is an internationally recognized standard for application of \nthe highest criteria toward animal welfare, care and usage. This accreditation \nexemplifies our dedication to excellence in animal care, which results in a \nbetter environment for animals and higher quality research for patients.\n13", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 12, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}